Inventor
ANKERSEN MICHAEL
DK33 patents
⚠️ This page may combine multiple inventors who share the name “ANKERSEN MICHAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVO NORDISK AS
29 patentsUS7384967B2Jun 10, 2008
Aryl carbonyl derivatives as therapeutic agents
NOVO NORDISK AS166 citations98
USRE45670ESep 15, 2015
Aryl carbonyl derivatives as therapeutic agents
NOVO NORDISK AS34 citations97
US7541373B2Jun 2, 2009
Aryl carbonyl derivatives as therapeutic agents
NOVO NORDISK AS123 citations97
US6013658AJan 11, 2000
Compounds with growth hormone releasing properties
NOVO NORDISK AS68 citations96
US5922770AJul 13, 1999
Compounds with growth hormone releasing properties
NOVO NORDISK AS50 citations96
US7598391B2Oct 6, 2009
Heteroaryl-ureas and their use as glucokinase activators
NOVO NORDISK AS14 citations92
US6939880B2Sep 6, 2005
Compounds with growth hormone releasing properties
NOVO NORDISK AS25 citations92
US6576648B2Jun 10, 2003
Compound with growth hormone releasing properties
NOVO NORDISK AS40 citations92
US6555570B2Apr 29, 2003
Compounds with growth hormone releasing properties
NOVO NORDISK AS27 citations92
US6303620B1Oct 16, 2001
Compounds with growth hormone releasing properties
NOVO NORDISK AS50 citations92
US6274584B1Aug 14, 2001
Compounds with growth hormone releasing properties
NOVO NORDISK AS30 citations92
US6127354AOct 3, 2000
Compounds with growth hormone releasing properties
NOVO NORDISK AS20 citations92
US6127391AOct 3, 2000
Compounds with growth hormone releasing properties
NOVO NORDISK AS33 citations92
US6127341AOct 3, 2000
Compounds with growth hormone releasing properties
NOVO NORDISK AS28 citations92
US5977178ANov 2, 1999
Compounds with growth hormone releasing properties
NOVO NORDISK AS31 citations92
US7897628B2Mar 1, 2011
Aryl carbonyl derivatives as therapeutic agents
NOVO NORDISK AS15 citations91
US7541430B2Jun 2, 2009
Peptides for use in treating obesity
NOVO NORDISK AS28 citations90
US6127343AOct 3, 2000
Somatostatin agonists and antagonists
NOVO NORDISK AS38 citations89
US6919315B1Jul 19, 2005
Compounds with growth hormone releasing properties
NOVO NORDISK AS17 citations87
US6020349AFeb 1, 2000
Constrained somatostatin agonists and antagonists
NOVO NORDISK AS39 citations87
USRE45183EOct 7, 2014
Heteroaryl-ureas and their use as glucokinase activators
NOVO NORDISK AS7 citations83
US7872139B2Jan 18, 2011
Heteroaryl-ureas and their use as glucokinase activators
NOVO NORDISK AS10 citations83
US7851636B2Dec 14, 2010
Heteroaryl-ureas and their use as glucokinase activators
NOVO NORDISK AS8 citations83
US6566337B1May 20, 2003
Compounds with growth hormone releasing properties
NOVO NORDISK AS14 citations81
US6350767B1Feb 26, 2002
Compounds with growth hormone releasing properties
NOVO NORDISK AS8 citations74
US6083908AJul 4, 2000
Compounds with growth hormone releasing properties
NOVO NORDISK AS12 citations74
US6159941ADec 12, 2000
Use of somatostatin agonists and antagonists for treating diseases related to the eye
NOVO NORDISK AS8 citations67
US6083960AJul 4, 2000
Constrained somatostatin agonists and antagonists
NOVO NORDISK AS4 citations57
US7576062B2Aug 18, 2009
Compounds with growth hormone releasing properties
NOVO NORDISK AS0 citations45